Genomma Lab Internacional Announces Results for the Third Quarter 2026
PR Newswire•21/10/2026•19:59 ET
0
Key Highlights
- ➤Q3 net sales rose 1.3% to MXN4,497.6 million
- ➤Net income increased 18.6% to MXN514.9 million
- ➤EBITDA margin reached 21.0%, down 271 basis points year over year
- ➤Latin America sales grew 12.2%, partly offset by US Hispanic retail disruption
- ➤Mexico sell-out returned to growth for the third consecutive quarter
Expert Statements
Marco Sparvieri, CEO of Genomma Lab Internacional
“Q3 2026 confirms that our recovery plan is working. Mexico improved for the third consecutive quarter and sell-out returned to growth, while market share held or grew across every business unit despite a soft market. Our late-June innovation is already driving +39% sell-out growth at clients carrying the new product, and Suerox reached a record 12.6% value share at our leading retailer. Consolidated net sales grew +1.3%, with Latin America up +12.2%. We protected profitability with a 21.0% EBITDA margin while reducing SG&A, and net income rose +18.6% on lower financing costs and a favorable FX result, with free cash flow also improving versus last year. We enter the fourth quarter with momentum, a stronger innovation pipeline and a solid balance sheet. On December 3rd in New York, we will present our new operating model, our execution commitments and our artificial intelligence platform in action, with measurable results and the ability to replicate winning playbooks across brands, functions and countries.”
Genomma Lab Internacional Announces Results for the Third Quarter 2026 PR Newswire
MEXICO CITY, Oct. 21, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the third quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.
Get started
Create a free account to read the full story.